A phase i escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 557-564

  Shirao, Kuniaki ^a,f   Yoshino, Takayuki ^b,g   Boku, Narikazu ^b   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Yasui, Hisateru ^a,h   Yamamoto, Nobuyuki ^b   Tanigawara, Yusuke ^c   Nolting, Arno ^d   Yoshino, Shinichiro ^e  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d MERCK KGAA   (Germany)

^e Merck Serono Co Ltd   (Japan)

^f OITA UNIVERSITY   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Cetuximab; Colorectal; EGFR; Japanese; Pharmacokinetics; Safety

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FEVER; HUMAN; JAPANESE; LUNG ADENOCARCINOMA; MALE; NAUSEA; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RECTUM CARCINOMA; SINGLE DRUG DOSE; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; TREATMENT DURATION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 67449146560     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0904-6     Document Type: Article

References (19)

1. NI Goldstein M Prewett K Zuklys P Rockwell J Mendelsohn 1995 Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1311 1318
2. S Li KR Schmitz PD Jeffrey JJ Wiltzius P Kussie KM Ferguson 2005 Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 301 311 (Pubitemid 40544648)
3. X Kang D Patel S Ng M Melchior D Ludwig D Hicklin 2007 High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab J Clin Oncol 25 (Abstr 3041)
4. J Kurai H Chikumi K Hashimoto K Yamaguchi A Yamasaki T Sako H Touge H Makino M Takata M Miyata M Nakamoto N Burioka E Shimizu 2007 Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines Clin Cancer Res 13 1552 1561 (Pubitemid 46450447)
5. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro D Bets M Mueser A Harstrick C Verslype I Chau E Van Cutsem 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 (Pubitemid 38944402)
6. Jonker DJ, Karapetis CS, Moore M, Zalcberg JR, Tu D, Berry S, Koski S, Krahn M, Simes J, Tebbutt N, Van Hazel G, O'Callaghan CJ (2007) Randomized phase III trial of cetuximab monotherapy plus best supportive care [BSC] versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor [EGFR]-positive colorectal carcinoma. A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). 98th AACR Annual Meeting, 14-18 April 2007, Los Angeles, USA (Abstr LB-1). Updated information presented at meeting
7. Scheithauer W, Sobrero A, Lenz H, Maurel J, Lutz M, Middleton G, Saleh M, Zubel A, Williams K, Burris III H (2007) Cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial. In: 14th European cancer conference, 23-27 September 2007, Barcelona, Spain (Abstr 3003)
8. Van Cutsem E, Bodoky G, Kyung Roh J, Folprecht G, Park Y, Van Laethem J, Raoul J, Ciardiello F, Lebrun P, Rougier P (2007) CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs FOLFIRI in first-line metastatic colorectal cancer (mCRC). In: 14th European cancer conference, Barcelona, Spain (Abstr 3001), 23-27 September (2007)
9. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur D Raben J Jassem R Ove MS Kies J Baselga H Youssoufian N Amellal EK Rowinsky KK Ang 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567 578 (Pubitemid 43209104)
10. Vermorken JB, Hitt R, Geoffrois L, Erfan J, Kawecki A, Zabolotnyy D, Schueler A, Knecht R, Benasso M, Kienzer H (2007) Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): efficacy and safety results of a randomized phase III trial (EXTREME). In: 14th European cancer conference, Barcelona, Spain (Abstr 5501), 23-27 September 2007
11. PM Fracasso H Burris 3rd MA Arquette R Govindan F Gao LP Wright SA Goodner FA Greco SF Jones N Willcut C Chodkiewicz A Pathak GM Springett GR Simon DM Sullivan R Marcelpoil SD Mayfield D Mauro CR Garrett 2007 A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing Clin Cancer Res 13 986 993 (Pubitemid 46340377)
12. AR Tan DF Moore M Hidalgo JH Doroshow EA Poplin S Goodin D Mauro EH Rubin 2006 Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors Clin Cancer Res 12 6517 6522 (Pubitemid 44799726)
13. K James E Eisenhauer M Christian M Terenziani D Vena A Muldal P Therasse 1999 Measuring response in solid tumors: unidimensional versus bidimensional measurement J Natl Cancer Inst 91 523 528 (Pubitemid 29157060)
14. C Delbaldo JY Pierga V Dieras S Faivre V Laurence JC Vedovato M Bonnay M Mueser A Nolting A Kovar E Raymond 2005 Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma Eur J Cancer 41 1739 1745 (Pubitemid 41132635)
15. TM) after single and multiple intravenous doses in cancer patient. American Society of Clinical Oncology-Gastrointestinal Cancers Symposium, San Francisco
16. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 (Pubitemid 41079832)
17. Van Cutsem E, Mayer RJ, Gold P, Stella PJ, Cohen A, Pippas AW, Windt P, Molloy P, Lenz H-J (2004) Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 28 September-1 October 2004, Geneva, Switzerland (Abstr 279)
18. RS Herbst M Arquette DM Shin K Dicke EE Vokes N Azarnia WK Hong MS Kies 2005 Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck J Clin Oncol 23 5578 5587 (Pubitemid 46300152)
19. HQ Xiong A Rosenberg A LoBuglio W Schmidt RA Wolff J Deutsch M Needle JL Abbruzzese 2004 Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial J Clin Oncol 22 2610 2616 (Pubitemid 41103748)